Metabolic features of clear-cell renal cell carcinoma: mechanisms and clinical implications

被引:49
作者
Pinthus, Jehonathan H. [1 ]
Whelan, Kaitlyn F. [1 ]
Gallino, Daniel [1 ]
Lu, Jian-Ping [1 ]
Rothschild, Nathan [1 ]
机构
[1] McMaster Univ, Dept Surg, Div Urol, Hamilton, ON L8S 4L8, Canada
来源
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL | 2011年 / 5卷 / 04期
关键词
FATTY-ACID SYNTHASE; POSITRON-EMISSION-TOMOGRAPHY; KIDNEY CANCER; ACYL-COENZYME; FDG PET; HYPOXIA; PATHWAY; RISK; CHOLESTEROL; EXPRESSION;
D O I
10.5489/cuaj.10196
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Central to the malignant behaviour that endows cancer cells with growth advantage is their unique metabolism. Cancer cells can process nutrient molecules differently from normal cells and use it to overcome stress imposed on them by various therapies. This metabolic conversion is controlled by specific genetic mutations that are associated with activation of oncogenes and loss of tumour suppressor proteins. Understanding these processes is important as it can lead to the discovery of biomarkers that can predict the aggressiveness of the disease and its response to therapy, and even more importantly, to the development of novel therapeutics. A classic tumour in this respect is clear-cell renal cell carcinoma (RCC). In this review, we will begin with a brief summary of normal cellular bioenergetic pathways, which will be followed by a description of the characteristic metabolism of glucose and lipids in clear-cell RCC cells and its clinical implications. Data relating to the potential effect of dietary nutrients on RCC will also be reviewed along with potential therapies targeted at interrupting specific metabolic pathways in clear-cell RCC.
引用
收藏
页码:274 / 282
页数:9
相关论文
共 76 条
[21]   FDG PET characterization of renal masses: Preliminary experience [J].
Goldberg, MA ;
MayoSmith, WW ;
Papanicolaou, N ;
Fischman, AJ ;
Lee, MJ .
CLINICAL RADIOLOGY, 1997, 52 (07) :510-515
[22]   The AMP-activated protein kinase pathway - new players upstream and downstream [J].
Hardie, DG .
JOURNAL OF CELL SCIENCE, 2004, 117 (23) :5479-5487
[23]   A new role for the von Hippel-Lindau tumor suppressor protein:: stimulation of mitochondrial oxidative phosphorylation complex biogenesis [J].
Hervouet, E ;
Demont, J ;
Pecina, P ;
Vojtísková, A ;
Houstek, J ;
Simonnet, H ;
Godinot, C .
CARCINOGENESIS, 2005, 26 (03) :531-539
[24]   3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis [J].
Horiguchi, A ;
Sumitomo, M ;
Asakuma, J ;
Asano, T ;
Asano, T ;
Hayakawa, M .
CLINICAL CANCER RESEARCH, 2004, 10 (24) :8648-8655
[25]   Fatty acid synthase over expression is an indicator of tumor aggressiveness and poor prognosis in renal cell carcinoma [J].
Horiguchi, Akio ;
Asano, Tomohiko ;
Asano, Takako ;
Ito, Keiichi ;
Sumitomo, Maikoto ;
Hayakawa, Masamichi .
JOURNAL OF UROLOGY, 2008, 180 (03) :1137-1140
[26]  
Horiguchi A, 2008, J UROLOGY, V180, P729, DOI 10.1016/j.juro.2008.03.186
[27]   Dietary vitamin C, E, and carotenoid intake and risk of renal cell carcinoma [J].
Hu, Jinfu ;
La Vecchia, Carlo ;
Negri, Eva ;
DesMeules, Marie ;
Mery, Les .
CANCER CAUSES & CONTROL, 2009, 20 (08) :1451-1458
[28]   HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability [J].
Isaacs, JS ;
Jung, YJ ;
Mole, DR ;
Lee, S ;
Torres-Cabala, C ;
Chung, YL ;
Merino, M ;
Trepel, J ;
Zbar, B ;
Toro, J ;
Ratcliffe, PJ ;
Linehan, WM ;
Neckers, L .
CANCER CELL, 2005, 8 (02) :143-153
[29]   Structural mechanism for statin inhibition of HMG-CoA reductase [J].
Istvan, ES ;
Deisenhofer, J .
SCIENCE, 2001, 292 (5519) :1160-1164
[30]   Complete radiological and metabolic response of metastatic renal cell carcinoma to SU5416 (semaxanib) in a patient with probable von Hippel-Lindau syndrome [J].
Jennens, RR ;
Rosenthal, MA ;
Lindeman, GJ ;
Michael, M .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2004, 22 (03) :193-196